BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

359 related articles for article (PubMed ID: 16580264)

  • 1. Triple-targeted oncolytic adenoviruses featuring the cox2 promoter, E1A transcomplementation, and serotype chimerism for enhanced selectivity for ovarian cancer cells.
    Bauerschmitz GJ; Guse K; Kanerva A; Menzel A; Herrmann I; Desmond RA; Yamamoto M; Nettelbeck DM; Hakkarainen T; Dall P; Curiel DT; Hemminki A
    Mol Ther; 2006 Aug; 14(2):164-74. PubMed ID: 16580264
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of chemotherapy resistant ovarian cancer with a MDR1 targeted oncolytic adenovirus.
    Rein DT; Volkmer A; Beyer IM; Curiel DT; Janni W; Dragoi A; Hess AP; Maass N; Baldus SE; Bauerschmitz G; Breidenbach M
    Gynecol Oncol; 2011 Oct; 123(1):138-46. PubMed ID: 21741695
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A fiber-modified, secretory leukoprotease inhibitor promoter-based conditionally replicating adenovirus for treatment of ovarian cancer.
    Rein DT; Breidenbach M; Kirby TO; Han T; Siegal GP; Bauerschmitz GJ; Wang M; Nettelbeck DM; Tsuruta Y; Yamamoto M; Dall P; Hemminki A; Curiel DT
    Clin Cancer Res; 2005 Feb; 11(3):1327-35. PubMed ID: 15709205
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased safety with preserved antitumoral efficacy on hepatocellular carcinoma with dual-regulated oncolytic adenovirus.
    Zhang Q; Chen G; Peng L; Wang X; Yang Y; Liu C; Shi W; Su C; Wu H; Liu X; Wu M; Qian Q
    Clin Cancer Res; 2006 Nov; 12(21):6523-31. PubMed ID: 17085667
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Functional interactions of antiapoptotic proteins and tumor necrosis factor in the context of a replication-competent adenovirus.
    Liu TC; Wang Y; Hallden G; Brooks G; Francis J; Lemoine NR; Kirn D
    Gene Ther; 2005 Sep; 12(17):1333-46. PubMed ID: 15920462
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A survivin-mediated oncolytic adenovirus induces non-apoptotic cell death in lung cancer cells and shows antitumoral potential in vivo.
    Li B; Liu X; Fan J; Qi R; Bo L; Gu J; Qian Q; Qian C; Liu X
    J Gene Med; 2006 Oct; 8(10):1232-42. PubMed ID: 16900558
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A fiber-modified mesothelin promoter-based conditionally replicating adenovirus for treatment of ovarian cancer.
    Tsuruta Y; Pereboeva L; Breidenbach M; Rein DT; Wang M; Alvarez RD; Siegal GP; Dent P; Fisher PB; Curiel DT
    Clin Cancer Res; 2008 Jun; 14(11):3582-8. PubMed ID: 18519792
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Utility of TK/GCV in the context of highly effective oncolysis mediated by a serotype 3 receptor targeted oncolytic adenovirus.
    Raki M; Hakkarainen T; Bauerschmitz GJ; Särkioja M; Desmond RA; Kanerva A; Hemminki A
    Gene Ther; 2007 Oct; 14(19):1380-8. PubMed ID: 17611584
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modulation of telomerase promoter tumor selectivity in the context of oncolytic adenoviruses.
    Bilsland AE; Merron A; Vassaux G; Keith WN
    Cancer Res; 2007 Feb; 67(3):1299-307. PubMed ID: 17283167
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A simplified system for generating oncolytic adenovirus vector carrying one or two transgenes.
    Hu ZB; Wu CT; Wang H; Zhang QW; Wang L; Wang RL; Lu ZZ; Wang LS
    Cancer Gene Ther; 2008 Mar; 15(3):173-82. PubMed ID: 18157145
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel ex vivo model system for evaluation of conditionally replicative adenoviruses therapeutic efficacy and toxicity.
    Kirby TO; Rivera A; Rein D; Wang M; Ulasov I; Breidenbach M; Kataram M; Contreras JL; Krumdieck C; Yamamoto M; Rots MG; Haisma HJ; Alvarez RD; Mahasreshti PJ; Curiel DT
    Clin Cancer Res; 2004 Dec; 10(24):8697-703. PubMed ID: 15623655
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ICOVIR-5 shows E2F1 addiction and potent antiglioma effect in vivo.
    Alonso MM; Cascallo M; Gomez-Manzano C; Jiang H; Bekele BN; Perez-Gimenez A; Lang FF; Piao Y; Alemany R; Fueyo J
    Cancer Res; 2007 Sep; 67(17):8255-63. PubMed ID: 17804740
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A capsid-modified, conditionally replicating oncolytic adenovirus vector expressing TRAIL Leads to enhanced cancer cell killing in human glioblastoma models.
    Wohlfahrt ME; Beard BC; Lieber A; Kiem HP
    Cancer Res; 2007 Sep; 67(18):8783-90. PubMed ID: 17875719
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A potent replicative delta-24 adenoviral vector driven by the promoter of human papillomavirus 16 that is highly selective for associated neoplasms.
    Delgado-Enciso I; Cervantes-García D; Martínez-Dávila IA; Ortiz-López R; Alemany-Bonastre R; Silva-Platas CI; Lugo-Trampe A; Barrera-Saldaña HA; Galván-Salazar HR; Coronel-Tene CG; Sánchez-Santillán CF; Rojas-Martínez A
    J Gene Med; 2007 Oct; 9(10):852-61. PubMed ID: 17729237
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chlorpromazine and apigenin reduce adenovirus replication and decrease replication associated toxicity.
    Kanerva A; Raki M; Ranki T; Särkioja M; Koponen J; Desmond RA; Helin A; Stenman UH; Isoniemi H; Höckerstedt K; Ristimäki A; Hemminki A
    J Gene Med; 2007 Jan; 9(1):3-9. PubMed ID: 17149790
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A bidirectional Tet-dependent promotor construct regulating the expression of E1A for tight control of oncolytic adenovirus replication.
    Fechner H; Wang X; Picó AH; Wildner J; Suckau L; Pinkert S; Sipo I; Weger S; Poller W
    J Biotechnol; 2007 Jan; 127(4):560-74. PubMed ID: 17083991
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-tumor efficacy of a transcriptional replication-competent adenovirus, Ad-OC-E1a, for osteosarcoma pulmonary metastasis.
    Li X; Jung C; Liu YH; Bae KH; Zhang YP; Zhang HJ; Vanderputten D; Jeng MH; Gardner TA; Kao C
    J Gene Med; 2006 Jun; 8(6):679-89. PubMed ID: 16570242
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel oncolytic adenoviruses targeted to melanoma: specific viral replication and cytolysis by expression of E1A mutants from the tyrosinase enhancer/promoter.
    Nettelbeck DM; Rivera AA; Balagué C; Alemany R; Curiel DT
    Cancer Res; 2002 Aug; 62(16):4663-70. PubMed ID: 12183423
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combining high selectivity of replication with fiber chimerism for effective adenoviral oncolysis of CAR-negative melanoma cells.
    Rivera AA; Davydova J; Schierer S; Wang M; Krasnykh V; Yamamoto M; Curiel DT; Nettelbeck DM
    Gene Ther; 2004 Dec; 11(23):1694-702. PubMed ID: 15496964
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potent antitumoral effects of targeted promoter-driven oncolytic adenovirus armed with Dm-dNK for breast cancer in vitro and in vivo.
    Dong X; Qu W; Ma S; Zhu Z; Zheng C; He A; Karlsson A; Xu K; Zheng X
    Cancer Lett; 2013 Jan; 328(1):95-103. PubMed ID: 23000515
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.